We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients

This study is currently recruiting participants.
Verified September 2017 by Novartis ( Novartis Pharmaceuticals )
Sponsor:
ClinicalTrials.gov Identifier:
NCT02228096
First Posted: August 28, 2014
Last Update Posted: September 29, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
  Purpose
This is a single arm, open-label, multi-center, phase II study to determine the efficacy and safety of an experimental therapy called CTL019 T-cells in pediatric patients with B-cell acute lymphoblastic leukemia, who are refractory to standard chemotherapy regimen or relapsed after allogeneic stem cell transplant

Condition Intervention Phase
B-cell Acute Lymphoblastic Leukemia Relapsed B-cell Acute Lymphoblastic Leukemia Refractory B-cell Acute Lymphoblastic Leukemia Biological: CTL019 T-cells Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia

Resource links provided by NLM:


Further study details as provided by Novartis ( Novartis Pharmaceuticals ):

Primary Outcome Measures:
  • Overall Remission Rate (ORR) [ Time Frame: within 6 months after CTL019 administration ]
    Overall Remission Rate (ORR), which includes Complete Remission (CR) and Complete Remission with Incomplete Blood Count Recovery (CRi), as determined by assessments of peripheral blood, bone marrow, CNS symptoms, physical exam (PE) and cerebrospinal fluid (CSF). The primary endpoint was based on the independent review committee (IRC) assessment.

  • Safety [ Time Frame: 12 months ]
    Adverse events and laboratory abnormalities (type, frequency and severity)


Estimated Enrollment: 67
Actual Study Start Date: August 14, 2014
Estimated Study Completion Date: October 17, 2024
Estimated Primary Completion Date: October 17, 2024 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: CTL019
Pediatric patients with relapsed/refractory B-cell ALL
Biological: CTL019 T-cells
A target dose of CTL019 transduced cells will consist of a single infusion of 2.0 to 5.0 x 10^6 CTL019 transduced cells per kg body weight (for patients ≤ 50 kg) and 1.0 to 2.5 x 10^8 CTL019 transduced viable T cells (for patients > 50 kg). The following cell dose ranges may be infused if all other safety release criteria are met: 0.2 to 5.0 x 10^6 CTL019 transduced viable T cells per kg body weight (for patient ≤ 50 kg) and 0.1 to 2.5 x 10^8 CTL019 transduced viable T cells (for patients > 50 kg).
Other Name: tisagenlecleucel

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   3 Years to 21 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Relapsed or refractory pediatric B-cell ALL:

    1. 2nd or greater Bone Marrow (BM) relapse OR
    2. Any BM relapse after allogeneic SCT and must be > 6 months from SCT at the time of CTL019 infusion OR
    3. Refractory as defined by not achieving a CR after 2 cycles of a standard chemotherapy regimen chemotherapy regimen or chemorefractory as defined by not achieving a CR after 1 cycle of standard chemotherapy for relapse leukemia OR
    4. Patients with Philadelphia chromosome positive (Ph+) ALL are eligible if they are intolerant to or have failed 2 lines of tyrosine kinase inhibitor therapy (TKI), or if TKI therapy is contraindicated OR
    5. Ineligible for allogeneic SCT
  • For relapsed patients, CD19 tumor expression demonstrated in bone marrow or peripheral blood by flow cytometry within 3 months of study entry
  • Adequate organ function defined as:

    1. Renal function defined as (Calculated creatinine clearance or radioisotope Glomerular Filtration Rate (GFR) > 60 mL/min/1.73 m2 OR serum creatinine based on age/gender
    2. Alanine Aminotransferase (ALT) < 5 times the upper limit of normal (ULN) for age;
    3. Bilirubin < 2.0 mg/dL;
    4. Must have a minimum level of pulmonary reserve defined as ≤Grade 1 dyspnea and pulse oxygenation > 91% on room air
    5. Left Ventricular Shortening Fraction (LVSF) ≥ 28% confirmed by echocardiogram, or Left Ventricular Ejection Fraction (LVEF) ≥ 45% confirmed by echocardiogram or MUGA within 7 days of screening
  • Bone marrow with ≥ 5% lymphoblasts by morphologic assessment at screening
  • Life expectancy > 12 weeks
  • Age 3 at the time of initial diagnosis to age 21 at the time of initial diagnosis
  • Karnofsky (age ≥ 16 years) or Lansky (age < 16 years) performance status ≥ 50 at screening
  • Signed written informed consent and assent forms (if applicable) must be obtained prior to any study procedures
  • Once all other eligibility criteria are confirmed, must have an apheresis product of non-mobilized cells received and accepted by the manufacturing site. Note: Apheresis product will not be shipped to or assessed for acceptance by the manufacturing site until documented confirmation of all other eligibility criteria is received.
  • Patients with active CNS leukemia involvement defined as CNS-3 by CSF findings only are eligible but will have their CTL019 infusion delayed until CNS disease is reduced to CNS-1 or CNS-2 by CSF findings. Patients with other forms of active CNS-3 leukemic involvement such as CNS parenchymal or ocular disease, cranial nerve involvement or significant leptomeningeal disease are not eligible. However, such patients with other forms of CNS-3 leukemic involvement (non-CSF involvement) are eligible if there is documented evidence of disease stabilization for at least 3 months prior to CTL019 infusion. Patients must have no acute/ongoing neurologic toxicity > Grade 1 with the exception of a history of controlled seizures or fixed neurologic deficits that have been stable/improving over the past 3 months.

Exclusion Criteria:

  • Isolated extra-medullary disease relapse
  • Patients with concomitant genetic syndrome: such as patients with Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndrome. Patients with Down Syndrome will not be excluded.
  • Patients with Burkitt's lymphoma/leukemia (i.e. patients with mature B-cell ALL, leukemia with B-cell [surface Immunoglobulin (sIg) positive and kappa or lambda restricted positivity] ALL, with FAB L3 morphology and /or a MYC translocation)
  • Prior malignancy, except carcinoma in situ of the skin or cervix treated with curative intent and with no evidence of active disease
  • Prior treatment with gene therapy product
  • Treatment with any prior anti-CD19/anti-CD3 therapy, or any other anti-CD19 therapy
  • Presence of Grade 2 to 4 acute or extensive chronic graft-versus-host disease (GVHD)
  • Patient has participated in an investigational research study using an investigational agent within the last 30 days prior to screening
  • Pregnant or nursing (lactating) women. NOTE: female study participants of reproductive potential must have a negative serum or urine pregnancy test performed within 48 hours before infusion
  • Active or latent hepatitis B or active hepatitis C (test within 8 weeks of screening), or any uncontrolled infection at screening
  • HIV positive test within 8 weeks of screening
  • The following medications are excluded:

    1. Steroids: Therapeutic systemic doses of steroids must be stopped > 72 hours prior to CTL019 infusion. However, the following physiological replacement doses of steroids are allowed: < 12 mg/m2/day hydrocortisone or equivalent
    2. Allogeneic cellular therapy: Any donor lymphocyte infusions (DLI) must be completed > 6 weeks prior to CTL019 infusion
    3. GVHD therapies: Any systemic drug used for GVHD must be stopped > 4 weeks prior to CTL019 infusion to confirm that GVHD recurrence is not observed (e.g. calcineurin inhibitors, methotrexate or other chemotherapy drugs, mycophenolyate, rapamycin, thalidomide, or immunosuppressive antibodies such as anti-CD20 (rituximab), anti-tumor necrosis factor [anti-TNF], anti-interleukin 6 [anti-IL6] or anti-interleukin 6 receptor [anti-IL6R], systemic steroids)
    4. Chemotherapy:
  • Tyrosine kinase inhibitors and hydroxyurea must be stopped > 72 hours prior to CTL019 infusion
  • The following drugs must be stopped > 1 week prior to CTL019 infusion and should not be administered concomitantly or following lymphodepleting chemotherapy: vincristine, 6-mercaptopurine, 6-thioguanine, methotrexate < 25 mg/m2, cytosine arabinoside < 100 mg/m2/day, asparaginase (non-pegylated)
  • The following drugs must be stopped >2 weeks prior to CTL019 infusion: salvage chemotherapy (e.g. clofarabine, cytosine arabinoside > 100 mg/m2, anthracyclines, cyclophosphamide, methotrexate ≥ 25 mg/m2), excluding the required lymphodepleting chemotherapy drugs
  • Pegylated-asparaginase must be stopped > 4 weeks prior to CTL019 infusion e. CNS disease prophylaxis:
  • CNS prophylaxis treatment must be stopped > 1 week prior to CTL019 infusion (e.g. intrathecal methotrexate) f. Radiotherapy:
  • Non-CNS site of radiation must be completed > 2 weeks prior to CTL019 infusion
  • CNS directed radiation must be completed > 8 weeks prior to CTL019 infusion g. Anti T-cell Antibodies: Administration of any T cell lytic or toxic antibody (e.g. alemtuzumab) within 8 weeks prior to CTL019 is prohibited since residual lytic levels may destroy the infused CTL019 cells and/or prevent their in vivo expansion. If such an agent has been administered within 8 weeks prior to CTL019, contact the Sponsor, consider consultation with an pharmacology expert, and consider measuring residual drug levels, if feasible, prior to CTL019 infusion Women of child-bearing potential (defined as all women physiologically capable of becoming pregnant) and all male participants, unless they are using highly effective methods of contraception for a period of 1 year after the CTL019 infusion. Highly effective contraception methods include:

    1. Total abstinence (when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are NOT acceptable methods of contraception
    2. Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment
    3. Male sterilization (at least 6 months prior to screening). For female patients on the study the vasectomized male partner should be the sole partner for that patient
    4. Use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception
    5. Use of IUDs are excluded due to increased risks of infection and bleeding in this population. However, IUD inserted prior to consent may remain in place, and a second method of contraception is mandated
    6. In case of use of oral contraception, women must be stable on the same pill for a minimum of 3 months before taking study treatment.

Women who are not of reproductive potential (defined as either <11 years of age, Tanner Stage 1, post-menopausal for at least 24 consecutive months (i.e. have had no menses) or have undergone hysterectomy, bilateral salpingectomy, and/or bilateral oophorectomy) are eligible without requiring the use of contraception. Women who are not yet of reproductive potential are to agree to use acceptable forms of contraception when they reach reproductive potential if within 1 year of CTL019 or if CAR cells are present in the blood by PCR. Acceptable documentation includes written or oral documentation communicated by clinician or clinician's staff of one of the following:

  1. Demographics show age < 11
  2. Physical examination indicates Tanner Stage 1
  3. Physician report/letter
  4. Operative report or other source documentation in the patient record
  5. Discharge summary
  6. Follicle stimulating hormone measurement elevated into the menopausal range
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02228096


Contacts
Contact: Novartis Pharmaceuticals 1-888-669-6682 novartis.email@novartis.com
Contact: Novartis Pharmaceuticals

Locations
United States, California
Childrens Hospital Los Angeles SC Recruiting
Los Angeles, California, United States, 90027
Contact: Renna Killen    323-361-2217    rkillen@chla.usc.edu   
Principal Investigator: Michael Pulsipher         
Stanford University Medical Center Recruiting
Palo Alto, California, United States, 94304
Contact: Neyssa Marina    650-724-9231    nmarina@stanford.edu   
Contact: Tina Baggott    650-497-7659    baggott@stanford.edu   
Principal Investigator: Kara Davis         
United States, Georgia
Children's Healthcare of Atlanta SC-2 Recruiting
Atlanta, Georgia, United States, 30342
Contact: Megan Hanby    404-785-7749    megan.hanby@choa.org   
Principal Investigator: Muna Qayed, MD         
United States, Michigan
University of Michigan Recruiting
Ann Arbor, Michigan, United States, 48109-5941
Contact: Jennifer Lay-Luskin    734-232-0744    jalay@med.umich.edu   
Principal Investigator: Rajen Mody, MD         
United States, Minnesota
University of Minnesota Medical Center Recruiting
Minneapolis, Minnesota, United States, 55455
Contact: Michael Verneris, MD    612-626-2961    verneris@umn.edu   
Contact: Stefanie Hage    612-625-6150    smhage@umn.edu   
Principal Investigator: Heather Stefanski         
United States, Missouri
Mercy Children's Kansas University Recruiting
Kansas City, Missouri, United States, 64108
Contact: Gary Myers, MD    816-983-6294    gdmyers@cmh.edu   
Contact: Rachel Wilcox    816-302-6973    rwilcox@cmh.edu   
Principal Investigator: Gary Myers, MD         
United States, North Carolina
Duke University Medical Center Recruiting
Durham, North Carolina, United States, 27708
Contact: Kristine Edwards    979-668-2967    kristine.gurganus@dm.duke.edu   
Contact: Christina Jenkins    919-668-8281    Christina.jenkins@duke.edu   
Principal Investigator: Paul Martin, MD         
United States, Ohio
Cincinnati Children's Hospital Recruiting
Cincinnati, Ohio, United States, 45230
Contact: Stella Davies, MD    513-636-1371    stella.davies@cchmc.org   
Contact: Stephanie Edwards    513-636-9292    stephaniel.edwards@cchmc.org   
Principal Investigator: Stella Davies, MD         
United States, Oregon
Oregon Health & Science University SC Recruiting
Portland, Oregon, United States, 97239
Contact: Jennifer Williamson    503-494-3639    willjenn@ohsu.edu   
Principal Investigator: Eneida Nemecek         
United States, Pennsylvania
Children's Hospital of Philadelphia Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Mark Duckworth    267-425-3149    duckworthm@email.chop.edu   
Contact: Christine Barker    267-425-5837    straitc@email.chop.edu   
Principal Investigator: Stephan Grupp, MD, PhD         
United States, Texas
University of Texas Southwestern Medical Center SC Recruiting
Dallas, Texas, United States, 75390-9034
Contact: Alison Patterson    214-456-2726    alison.patterson@childrens.com   
Principal Investigator: Theodore Laetsch, MD         
United States, Utah
University of Utah Recruiting
Salt Lake City, Utah, United States, 84113
Contact: Sam Sorenson    801-587-7484    samuel.sorenson@hsc.utah.edu   
Contact: Luke Stone    801-213-3395    luke.stone@hsc.utah.edu   
Principal Investigator: Michael Boyer, MD         
United States, Wisconsin
University of Wisconsin Hospital and Clinics Recruiting
Madison, Wisconsin, United States, 53705
Contact: Jenny Weiland    608-890-8070    PedsHemOncResearch@lists.wisc.edu   
Contact: Celeste Matsusjima    608-890-8069    camatsus@pediatrics.wisc.edu   
Principal Investigator: Christian Capitini, MD         
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

Additional Information:
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT02228096     History of Changes
Other Study ID Numbers: CCTL019B2205J
First Submitted: August 26, 2014
First Posted: August 28, 2014
Last Update Posted: September 29, 2017
Last Verified: September 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

URL: http://

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Novartis ( Novartis Pharmaceuticals ):
relapsed/refractory
Philadelphia chromosome positive acute lymphoblastic leukemia
Pharmaceuticals
Philadelphia chromosome positive
Acute Lymphoid Leukemia (ALL)
Acute Lymphocytic Leukemia (ALL)

Additional relevant MeSH terms:
Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Lymphoid
Burkitt Lymphoma
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Epstein-Barr Virus Infections
Herpesviridae Infections
DNA Virus Infections
Virus Diseases
Tumor Virus Infections
Lymphoma, B-Cell
Lymphoma, Non-Hodgkin
Lymphoma